This VTCN1 antibody is conjugated to PE/Dazzle™ 594
Application
Flow Cytometry (FACS)
Purification
The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.
B7h4 antibody, B7s1 antibody, B7x antibody, BC032925 antibody, B7-H4 antibody, B7H4 antibody, B7S1 antibody, B7X antibody, B7h.5 antibody, PRO1291 antibody, VCTN1 antibody, RGD1311204 antibody, V set domain containing T cell activation inhibitor 1 L homeolog antibody, V-set domain containing T cell activation inhibitor 1 antibody, V-set domain containing T-cell activation inhibitor 1 antibody, V set domain containing T cell activation inhibitor 1 antibody, vtcn1.L antibody, VTCN1 antibody, vtcn1 antibody, Vtcn1 antibody
Background
B7-H4, also known as VTCN1, is a type I transmembrane protein and member of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.